The Complicated Intra-abdominal Infection (cIAI) Market is driven by major players such as: MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, and Nosopharm. These companies are at the forefront of development. Innovative treatments address growing medical needs in the cIAI field, leading to dynamic market growth and potential breakthroughs in infection control.
DelveInsight's "Complex Intra-abdominal Infections - Market Insights, Epidemiology, and Market Forecasts - 2032" [https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr”. In-depth understanding of complex intra-abdominal infections, covering historical and projected epidemiology, as well as market trends in the US, EU5 (Germany, Spain, Italy, France, UK), and Japan.
Key facts of the Complex Intra-abdominal Infections market report:
- According to IDSA (2024), complicated intra-abdominal infection (cIAI) is commonly encountered in clinical practice, and appendicitis alone affects approximately 670,000 patients annually worldwide.
- A study by Labriciosa et al. (2018) recorded a total of 4,040 cIAIs, with 92.1% classified as community-acquired (CA-cIAI) and 7.9% as nosocomial-acquired (HA-cIAI).
- In February 2025, the FDA approved a fixed-dose intravenous combination of aztreonam and avibactam, along with metronidazole (Metrogel; Galderma Labs), for adults 18 years and older and limited treatment options for cIAI. This approval covers infectious diseases caused by: like gram-negative bacteriaEscherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia dies。
- In February 2025, AbbVie announced FDA approval for Embraveo (aztreonam and avibactam) in combination with metronidazole for adults with cIAI and limited treatment options.
- Major companies in the CIAI market include Merlion Pharmaceuticals, AiCuris, Novartis, Arecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Itelm Therapeutics, Nosopharm, and others.
To get detailed insights on the Complex Intra-abdominal Infections market outlook, drug intake, treatment scenarios, and epidemiological trends, click here: [https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr]
Overview of complicated intra-abdominal infections
Complicated intra-abdominal infection (cIAI) is a severe infection that extends beyond the organ of origin into the peritoneal cavity, often resulting in abscess formation, peritonitis, and sepsis. These infections are commonly caused by Polymicrobial pathogens, including Gram-negative bacteria, anaerobes, and fungi, makes treatment complex.
Effective management of CIAI includes a combination of broad-spectrum antibiotics and surgical intervention for source control. However, the increase in multidrug-resistant pathogens, such as ESBL-producing Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa, has increased demand for new treatment options. The CIAI market continues to evolve with advances in antimicrobial therapies, improved diagnostic tools, and enhanced infection control strategies.
Get a Free Sample of the Complex Intra-abdominal Infections Market Report:
[https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr]
Epidemiology of complex intra-abdominal infections
The Epidemiology section provides insights about past, current, and projected epidemiology trends in seven major markets (7MM) from 2019 to 2032. It helps to identify the causes of current and predicted trends by exploring numerous studies and views of key opinion leaders. The Epidemiology section also provides a detailed analysis of diagnosed patient populations and future trends.
Epidemiological segmentation of complex intra-abdominal infections
The Epidemiology chapter in the report is provided below as Historical and Projected Epidemiology, segmented as follows:
Total number of IAI incidents in the US
Total number of cIAI incidents in the US
cIAI Case Studies Based on Location of Acquisition in the United States
Examples of cIAI gender-specific cases in the United States
Incident cases by type of cIAI in the United States
Download the report to understand the factors driving epidemiological trends:
[https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr]
Complex intra-abdominal infections Drug intake and pipeline development
The drug uptake section focuses on the uptake rates of potential drugs recently launched in the CIAI Market or expected to be launched during the study period. The analysis covers drug intake, patient intake by treatment, and sales volume of each drug.
Additionally, a treatment evaluation section helps understand the most rapidly taken drugs and the reasons behind their maximum use. Additionally, it compares medicines based on market share.
This report also highlights pipeline development activity in complex intra-abdominal infections. , provides valuable insights about the different therapeutic candidates at different stages, and the key companies involved in the development of targeted therapies. It also analyzes recent collaborations, acquisitions, mergers, and licensing agreements for new treatments.
Strengths of the complex intra-abdominal infection market
The development of novel broad-spectrum antibiotics and combination therapy has improved treatment outcomes for drug-resistant infections.
Increased awareness among healthcare workers and advances in rapid diagnostic techniques enhance early detection and timely intervention.
Weaknesses of the Complex Intra-abdominal Infection Market
The emergence of multidrug-resistant pathogens, such as ESBL-producing Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa, limits treatment options.
The economic burden of long hospital stays, surgical interventions, and advanced antibiotic therapy makes treatments difficult to access, especially in low-income areas.
Complex Intra-abdominal Infections Market Report Scope
Study period: 2019-2032
Coverage: 7MM (US, EU5 [Germany, France, Italy, Spain, UK], and Japan)
Major companies: MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, etc.
Therapeutic evaluation: current and emerging treatments on the market
Market Trends: Market Drivers and Barriers
Competitor Intelligence Analysis: SWOT Analysis, PESTLE Analysis, Porter's Five Forces, BCG Matrix, Market Entry Strategy
Unmet needs, KOL views, analyst perspectives, market access, reimbursement
To explore the key players and advances in the cIAI treatment landscape, visit: :
[https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr]
table of contents
- Complex Intra-abdominal Infections Market Report Overview
- Overview of complicated intra-abdominal infections
- SWOT analysis of complicated intra-abdominal infections
- Summary of patient proportion (%) with complicated intra-abdominal infections
- Complex Intra-abdominal Infections Market Overview
- Disease background and overview of complicated intra-abdominal infections
- Epidemiology and patient population of complex intra-abdominal infections
- Number of patients with complicated intra-abdominal infections by country
- Current treatments and medical practices for complex intra-abdominal infections
- Unmet needs in complex intra-abdominal infections
- New treatments for complex intra-abdominal infections
- Complex Intra-abdominal Infections Market Outlook
13.Complex Intra-abdominal Infections Market Analysis by Countries (2019-2032)
- Market Access and Reimbursement of Treatments for Complex Intra-abdominal Infections
15.Complex Intra-abdominal Infections Market Drivers
- Complex Intra-abdominal Infections Market Barriers
- Complex intra-abdominal infections appendix
- How to report a complicated intra-abdominal infection
- DelveInsight Features
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare business consultant and market research firm specializing in life sciences. We support pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance.
We also provide healthcare consulting services that help you analyze the market to accelerate business growth and overcome challenges with a practical approach.
Contact information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
English
French